Despite a lackluster 2016, the pharmaceutical sector seems to be performing well overall in 2017 as the Investing News Network (INN) takes a look at the top gaining pharmaceutical stocks on the NASDAQ.
Any life science investing sector comes with inherent risk, but this year investors have had plenty of opportunities to cash in with smaller companies in the pharmaceutical sector innovating cancer therapies and advancing the oncology sector as a whole.
As investors look ahead to the remainder of 2017, the INN profiles the top pharma stocks NASDAQ year-to-date. The companies listed below have market caps of less than $500 million. All figures and numbers are current as of market closing time on July 10, 2017, with data compiled from Google Finance. The top pharma stocks NASDAQ list was obtained thanks to a list from NASDAQ of small and micro-cap companies.
1. Intec Pharma (NASDAQ:NTEC)
Market cap: $74.87; year-to-date percentage gain: 1262.5 percent; current share price: $5.45
First on our top pharma stocks NASDAQ list is Intec is a biopharmaceutical company based in Israel. The Accordion Pill is the company’s lead technology delivery system. Intec is set to release topline data from an ongoing trial in Parkinson’s disease with candidate AP-CDLD. The trial is expected to be completed in the fourth quarter of the year.
The company also has candidates for the treatment of insomnia and a cannabinoid-based pain management agent, which began its clinical trial process this year. Intec plans to use its Accordion Pill platform in coordination with cannabidiol (CBD) and tetrahydrocannabinol (THC) and will be used to treat lower back pain and Fibromyalgia.
Intec recently went through a management change-up with long time life sciences executive Jeffrey Meckler stepping into the role of CEO.
“We face significant opportunities with our late-stage program in Parkinson’s disease,” Meckler said in a statement. “In addition we have a versatile platform technology that can improve the efficacy and safety of existing and development-stage drugs by utilizing a proprietary gastric retention mechanism.”
2. AVEO Pharmaceuticals (NASDAQ:AVEO)
Market cap: $399.15 million; year-to-date percentage gain: 483.33 percent; current share price: $3.15
AVEO is a biopharmaceutical company working on the oncology sector alongside other unmet medical sectors.
The company saw a recent boost in its stock due to the recommendation from the scientific committee of the European Medicines Agency, for FOTIVDA (tivozanib) to treat patients with advanced renal cell carcinoma.
If the regulatory agency approves tivozanib AVEO is set to cash in by adding $4 million from a research and development reimbursement payment from EUSA Pharma.
“AVEO will also be eligible for up to $12 million in additional milestones from EUSA based on member state reimbursement and regulatory approvals,” Michael Bailey, president and chief executive officer of AVEO said in a statement.
3. CymaBay Therapeutics (NASDAQ:CBAY)
Market cap: $158.18 million; year-to-date percentage gain: 220.81 percent; current share price: $5.55
This clinical stage biopharmaceutical is working on therapies that would go against metabolic diseases. CymaBay also has a focus on orphan diseases.
CymaBay currently has three candidate products in the trial process with arhalofenate, an anti-inflammatory uricosuric drug, set to enter the third phase of its trials.
During the company’s first-quarter update and financial report release, it was revealed CymaBay saw a net loss of $5.4 million, a $1.4 million from the loss during the same period of time last year.
“We believe we are well positioned to advance our lead development candidate, seladelpar, for patients with primary biliary cholangitis (PBC), and to subsequently implement a broader strategy to expand the development of seladelpar in other liver diseases, including nonalcoholic steatohepatitis (NASH),” interim president and CEO Sujal Shah said in a statement.
4. Verastem (NASDAQ:VSTM)
Market cap: $133.91 million; year-to-date percentage gain: 208.04 percent; current share price: $3.45
Closing out our top pharma stocks NASDAQ list is Verastem, which is a clinical stage biopharmaceutical focused on drugs to help patients with cancer treatments.
Their product pipeline includes Duvelisib, which is being tested in four different trials, one of which is expected to produce topline data by mid-year.
Most recently the company announced the presentation of long-term follow-up data from the DYNAMO study evaluating duvelisib in patients with indolent non-Hodgkin lymphoma whose disease is refractory to both rituximab and chemotherapy or radioimmunotherapy.
Dr. Pier Luigi Zinzani from the University of Bologna Institute of Hematology and an investigator in the study said he believes oral duvelisib “has the potential to be an important new treatment option for lymphoma patients.”
In the company’s financial disclosure for the first quarter of 2017 Robert Forrester, president and CEO of Verastem said the company believes duvelisib has potential as a “convenient” treatment for patients with lymphomas.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.